Developing Therapeutics for Bipolar Disorder (BPD): From Animal Models to the Clinic

Animal and Translational Models for CNS Drug Discovery

Volumn , Issue , 2008, Pages 263-300

  Large, Charles H ^a   Einat, Haim ^b   Mahableshwarkar, Atul R ^c,d,e  

^a GSK   (Italy)

^b UNIVERSITY OF MINNESOTA   (United States)

^c GLAXOSMITHKLINE   (United States)

^d ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^e TAKEDA PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79952190583     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-373861-5.00009-6     Document Type: Chapter

References (209)

1. E. Kraeplin (1921) Manic-Depressive Insanity and Paranoia. Edinburgh, UK: E & S Livingston
2. J.D. Campbell (1952) Manic depressive psychosis in children. J Nerv Ment Dis 116(5), 424-439.
3. N.C. Andreasen (2007) DSM and the death of phenomenology in America: An example of unintended consequences. Schizophr Bull 33(1), 108-112.
4. American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental disorders, Fourth Edition, Text Revision. Washington, DC, USA: American Psychiatric Press
5. World Health Organization (2007) International Statistical Classification of Diseases and Related Health Problems (The) ICD-10 Second Edition 2007. Geneva, Switzerland: World Health Organization
6. Jamison, K.R. (1995). An Unquiet Mind. Alfred A. Knopf, a division of Random House, Inc.
7. Jaspers, K. (1968). General Psychopathology. Translated by Honeig, J. and Hamiltion, M.W. (Ed.), University of Chicago Press, Chicago, USA. Republished by Johns Hopkins University Press, 1997.
8. B. Rush (1812) Medical Inquiries and Observations upon the Diseases of the Mind. Philadelphia, USA: Kimber and Richardson
9. Goodwin, F.K. and Jamison, K.R. (2007). Manic-Depressive Illness; Bipolar Disorders and Recurrent Depression, Oxford University Press, Oxford, UK.
10. G. Winokur, P.J. Clayton and T. Reich (1969) Manic Depressive Illness. St. Louis, USA: CV Mosby
11. T. Deckersbach, R.H. Perlis, W.G. Frankle, S.M. Gray, L. Grandin, D.D. Dougherty, et al. (2004) Presence of irritability during depressive episodes in bipolar disorder. CNS Spectr 9(3), 227-231.
12. N.C. Andreasen (1979) Thought, language, and communication disorders. I. Clinical assessment, definition of terms, and evaluation of their reliability. Arch Gen Psychiatry 36(12), 1315-1321.
13. F. Cassidy, E. Ahearn and B.J. Carroll (2001) A prospective study of inter-episode consistency of manic and mixed subtypes of bipolar disorder. J Affect Disord 67(1–3), 181-185.
14. J. Kotin and F.K. Goodwin (1972) Depression during mania: Clinical observations and theoretical implications. Am J Psychiatry 129(6), 679-686.
15. M. Tohen, C.M. Waternaux and M.T. Tsuang (1990) Outcome in mania. A 4-year prospective follow-up of 75 patients utilizing survival analysis. Arch Gen Psychiatry 47(12), 1106-1111.
16. M.J. Gitlin, J. Swendsen, T.L. Heller and C. Hammen (1995) Relapse and impairment in bipolar disorder. Am J Psychiatry 152(11), 1635-1640.
17. M.B. Keller, P.W. Lavori, W. Coryell, J. Endicott and T.I. Mueller (1993) Bipolar I: A five-year prospective follow-up. J Nerv Ment Dis 181(4), 238-245.
18. L.L. Judd, H.S. Akiskal, P.J. Schettler, J. Endicott, J. Maser, D.A. Solomon, et al. (2002) The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 59(6), 530-537.
19. R.T. Joffe, G.M. MacQueen, M. Marriott and Y.L. Trevor (2004) A prospective, longitudinal study of percentage of time spent ill in patients with bipolar I or bipolar II disorders. Bipolar Disord 6(1), 62-66.
20. P.E. Keck Jr, S.L. McElroy, S.M. Strakowski, M.L. Bourne and S.A. West (1997) Compliance with maintenance treatment in bipolar disorder. Psychopharmacol Bull 33(1), 87-91.
21. J.F. Cade (2000) Lithium salts in the treatment of psychotic excitement. 1949. Bull World Health Organ 78(4), 518-520.
22. American Psychiatric Association. (2002). Practice Guidelines for the Treatment of Patients with Bipolar Disorder, American Psychiatric Association, Arlington, VA.
23. G.M. Goodwin and A.H. Young (2003) The British Association for Psychopharmacology guidelines for treatment of bipolar disorder: A summary. J Psychopharmacol 17(4 Suppl), 3-6.
24. J.R. Calabrese, R.M. Hirschfeld, M. Reed, M.A. Davies, M.A. Frye, P.E. Keck, et al. (2003) Impact of bipolar disorder on a U.S. community sample. J Clin Psychiatry 64(4), 425-432.
25. R.J. Wyatt and I. Henter (1995) An economic evaluation of manic-depressive illness – 1991. Soc Psychiatry Psychiatr Epidemiol 30(5), 213-219.
26. C.E. Begley, J.F. Annergers and A.C. Swann (2001) The lifetime cost of Bipolar disorder in the US: An estimate for new cases in 1998. Pharmacoeconomics 9 483-495.
27. L. Bryant-Comstock, M. Stender and G. Devercelli (2002) Health care utilization and costs among privately insured patients with bipolar I disorder. Bipolar Disord 4(6), 398-405.
28. G.S. Sachs (2003) Unmet clinical needs in bipolar disorder. J Clin Psychopharmacol 23(3 Suppl 1), S2-S8.
29. R.M. Hirschfeld, L. Lewis and L.A. Vornik (2003) Perceptions and impact of bipolar disorder: How far have we really come? Results of the national depressive and manic-depressive association 2000 survey of individuals with bipolar disorder. J Clin Psychiatry 64(2), 161-174.
30. E.P. Hayden and J.I. Nurnberger Jr (2006) Molecular genetics of bipolar disorder. Genes Brain Behav 5(1), 85-95.
31. T. Kato (2007) Molecular genetics of bipolar disorder and depression. Psychiatry Clin Neurosci 61(1), 3-19.
32. A. Farmer, A. Elkin and P. McGuffin (2007) The genetics of bipolar affective disorder. Curr Opin Psychiatry 20(1), 8-12.
33. R. Sherazi, P. McKeon, M. McDonough, I. Daly and N. Kennedy (2006) What’s new? The clinical epidemiology of bipolar I disorder. Harv Rev Psychiatry 14(6), 273-284.
34. R.M. Post and G.S. Leverich (2006) The role of psychosocial stress in the onset and progression of bipolar disorder and its comorbidities: The need for earlier and alternative modes of therapeutic intervention. Dev Psychopathol 18(4), 1181-1211.
35. C.L. Bowden (2004) Making optimal use of combination pharmacotherapy in bipolar disorder. J Clin Psychiatry 65(Suppl 15), 21-24.
36. R.M. Post, T.A. Ketter, P.J. Pazzaglia, K. Denicoff, M.S. George, A. Callahan, et al. (1996) Rational polypharmacy in the bipolar affective disorders. Epilepsy Res Suppl 11 153-180.
37. A.D. Roses (2006) On the discovery of the genetic association of Apolipoprotein E genotypes and common late-onset Alzheimer disease. J Alzheimers Dis 9(3 Suppl), 361-366.
38. G. Hasler, W.C. Drevets, T.D. Gould, I.I. Gottesman and H.K. Manji (2006) Toward constructing an endophenotype strategy for bipolar disorders. Biol Psychiatry 60(2), 93-105.
39. J.F. Cryan and D.A. Slattery (2007) Animal models of mood disorders: Recent developments. Curr Opin Psychiatry 20(1), 1-7.
40. R.H. Lenox, T.D. Gould and H.K. Manji (2002) Endophenotypes in bipolar disorder. Am J Med Genet 114(4), 391-406.
41. J.C. Chou and L. Fazzio (2006) Maintenance treatment of bipolar disorder: Applying research to clinical practice. J Psychiatr Pract 12(5), 283-299.
42. L.J. Hayes and D. Delgado (2007) Invited commentary on animal models in psychiatry: Animal models of non-conventional human behavior. Behav Genet 37(1), 11-17.
43. M.E. Seligman, S.F. Maier and J.H. Geer (1968) Alleviation of learned helplessness in the dog. J Abnorm Psychol 73(3), 256-262.
44. M.E. Seligman and S.F. Maier (1967) Failure to escape traumatic shock. J Exp Psychol 74(1), 1-9.
45. S. Leucht, W. Kissling and J. McGrath (2007) Lithium for schizophrenia. Cochrane Database Syst Rev 3 CD003834.
46. H. Einat (2007) Establishment of a battery of simple models for facets of bipolar disorder: A practical approach to achieve increased validity, better screening and possible insights into endophenotypes of disease. Behav Genet 37(1), 244-255.
47. J.W. Young, A. Minassian, M.P. Paulus, M.A. Geyer and W. Perry (2007) A reverse-translational approach to bipolar disorder: Rodent and human studies in the Behavioral Pattern Monitor. Neurosci Biobehav Rev 31(6), 882-896.
48. H. Einat, A. Shaldubina, Y. Bersudskey and R.H. Belmaker (2007) Prospects for the development of animal models for the study of bipolar disorder. J.C. Soares, A.H. Young (Eds) Bipolar Disorders: Basic Mechanisms and Therapeutic Implications New York: Taylor & Francis
49. Antelman, S.M., Caggiula, A.R., Kucinski, B.J., Fowler, H., Gershon, S., Edwards, D.J., Austin, M.C., Stiller, R., Kiss, S., and Kocan, D. (1998). The effects of lithium on a potential cycling model of bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry, 22(3): 495 – 510.
50. Eckermann, K., Beasley, A., Yang, P., Gaytan, O., Swann, A., and Dafny, N. (2001). Methylphenidate sensitization is modulated by valproate. Life Sci, 69(1): 47 – 57.
51. H. Einat and P. Yuan (2007) Protein kinase C inhibition by tamoxifen antagonizes manic-like behavior in rats: Implications for the development of novel therapeutics for bipolar disorder. J Pharmacol Exp Ther 55(3–4), 123-131.
52. R. Hamburger-Bar and M. Robert (1986) Interstrain correlation between behavioural effects of lithium and effects on cortical cyclic AMP. J Pharmacol Exp Ther 24(1), 9-13.
53. M. Namima and K. Sugihara (1999) Quantitative analysis of the effects of lithium on the reverse tolerance and the c-Fos expression induced by methamphetamine in mice. J Pharmacol Exp Ther 4(1), 11-18.
54. Post (1989) Sensitization, kindling, and anticonvulsants in mania. J Pharmacol Exp Ther 50(Suppl), 23-30.
55. R.H. Belmaker, B. Lerer, E. Klein and R. Hamburger (1982) The use of behavioral methods in the search for compounds with lithium-like activity. J Neurosci 21(1), 305-313.
56. R.J. Ralph, M.P. Paulus and M.A. Geyer (2001) Lithium prevention of amphetamine-induced ‘manic’ excitement and of reserpine-induced ‘depression’ in mice: possible role of 2-phenylethylamine. Psychopharmacology (Berl) 59(3), 259-262.
57. R.J. Ralph, M.P. Paulus and M.A. Geyer (2001) Regular induction of hypomania by L-dopa in “bipolar” manic-depressive patients. Nature 229(5280), 135-136.
58. R.J. Ralph, M.P. Paulus and M.A. Geyer (2001) Attenuation of the euphoriant and activating effects of d- and l-amphetamine by lithium carbonate treatment. Psychopharmacologia 44(3), 215-224.
59. R.J. Ralph, M.P. Paulus and M.A. Geyer (2001) The effect of lithium on amphetamine-induced locomotor stimulation. Psychopharmacology (Berl) 59(1), 41-45.
60. T.J. Gould, R.A. Keith and R.V. Bhat (2001) Differential sensitivity to lithium’s reversal of amphetamine-induced open-field activity in two inbred strains of mice. Behav Brain Res 118(1), 95-105.
61. P. Cappeliez and E. Moore (1990) Effects of lithium on an amphetamine animal model of bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 14(3), 347-358.
62. R.P. Ebstein, S. Eliashar, R.H. Belmaker, Y. Ben-Uriah and S. Yehuda (1980) Chronic lithium treatment and dopamine-mediated behavior. Biol Psychiatry 15(3), 459-467.
63. T.D. Gould, K.C. O’Donnell, A.M. Picchini and H. Manji (2007) Strain differences in lithium attenuation of d-amphetamine-induced hyperlocomotion: a mouse model for the genetics of clinical response to lithium. Neuropsychopharmacology 32(6), 1321-1333.
64. Hiscock, K., Linde, J., and Einat, H. (2007). Black Swiss mice as a new animal model for mania: a preliminary study. J Med Biol Sci, 1(2).
65. Ralph, R.J., Paulus, M.P., and Geyer, M.A. (2001). Strain-specific effects of amphetamine on prepulse inhibition and patterns of locomotor behavior in mice. J Pharmacol Exp Ther, 298(1):148–155.
66. Beaulieu, J.M., Sotnikova, T.D., Yao, W.D., Kockeritz, L., Woodgett, J.R., Gainetdinov, R.R., and Caron, M.G. (2004). Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci USA, 101(14):5099–5104.
67. Le-Niculescu, H., McFarland, M.J., Ogden, C.A., Balaraman, Y., Patel, S., Tan, J., Rodd, Z.A., Paulus, M., Geyer, M.A., Edenberg, H.J., Glatt, S.J., Faraone, S.V., Nurnberger, J.I., Kuczenski, R., Tsuang, M.T., and Niculescu, A.B. (2008). Phenomic, convergent functional genomic, and biomarker studies in a stress-reactive genetic animal model of bipolar disorder and co-morbid alcoholism. Am J Med Genet B Neuropsychiatr Genet, 147(2):134–166.
68. R.J. Ralph, M.P. Paulus, F. Fumagalli, M.G. Caron and M.A. Geyer (2001) Prepulse inhibition deficits and perseverative motor patterns in dopamine transporter knock-out mice: Differential effects of D1 and D2 receptor antagonists. J Neurosci 21(1), 305-313.
69. R.J. Ralph, G.B. Varty, M.A. Kelly, Y.M. Wang, M.G. Caron, M. Rubinstein, et al. (1999) The dopamine D2, but not D3 or D4, receptor subtype is essential for the disruption of prepulse inhibition produced by amphetamine in mice. J Neurosci 19(11), 4627-4633.
70. R. Arban, G. Maraia, K. Brackenborough, L. Winyard, A. Wilson, P. Gerrard, et al. (2005) Evaluation of the effects of lamotrigine, valproate and carbamazepine in a rodent model of mania. Behav Brain Res 158(1), 123-132.
71. P. Armitage, R. Rushton and H. Steinberg (1968) Interactions of chlordizepoxide and dexamphetamine in rats. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol 259(2), 150-151.
72. C.G. Aylmer, H. Steinberg and R.A. Webster (1987) Hyperactivity induced by dexamphetamine/chlordiazepoxide mixtures in rats and its attenuation by lithium pretreatment: A role for dopamine? Psychopharmacology (Berl) 91(2), 198-206.
73. R. Rushton and H. Steinberg (1966) Combined effects of chlordiazepoxide and dexamphetamine on activity of rats in an unfamiliar environment. Nature 211(5055), 1312-1313.
74. Serpa, K.A. (1999). Chlordiazepoxide/d-d-amphetamine induced hyperactivity in rats: assessment as mania model using automated activity chambers. Meltzer, L.T. (Ed.) Soc Neurosci Abstr, 25, 533.13.
75. B.J. Cao and N.A. Peng (1993) Magnesium valproate attenuates hyperactivity induced by dexamphetamine-chlordiazepoxide mixture in rodents. Eur J Pharmacol 237(2–3), 177-181.
76. A.L. Vale and F. Ratcliffe (1987) Effect of lithium administration on rat brain 5-hydroxyindole levels in a possible animal model for mania. Psychopharmacology (Berl) 91(3), 352-355.
77. Y. Lamberty, D.G. Margineanu and H. Klitgaard (2001) Effect of the new antiepileptic drug levetiracetam in an animal model of mania. Epilepsy Behav 2(5), 454-459.
78. P.W. Butler, G.M. Besser and H. Steinberg (1968) Changes in plasma cortisol induced by dexamphetamine and chlordiazepoxide given alone and in combination in man. J Endocrinol 40(3), 391-392.
79. G.M. Besser and H. Steinberg (1967) The interaction of chlordiazepoxide and dexamphetamine in man. Therapie 22(5), 977-990.
80. H. Ashton and A.H. Young (2003) GABA-ergic drugs: Exit stage left, enter stage right. J Psychopharmacol 17(2), 174-178.
81. T.A. Ketter and P.W. Wang (2003) The emerging differential roles of GABAergic and antiglutamatergic agents in bipolar disorders. J Clin Psychiatry 64(Suppl 3), 15-20.
82. P.W. Kalivas, B.A. Sorg and M.S. Hooks (1993) The pharmacology and neural circuitry of sensitization to psychostimulants. Behav Pharmacol 4(4), 315-334.
83. R.C. Pierce and P.W. Kalivas (1997) A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Res Brain Res Rev 25(2), 192-216.
84. R.M. Post, S.R. Weiss and A. Pert (1988) Cocaine-induced behavioral sensitization and kindling: Implications for the emergence of psychopathology and seizures. Ann N Y Acad Sci 537 292-308.
85. L. Herman, T. Hougland and R.S. El Mallakh (2007) Mimicking human bipolar ion dysregulation models mania in rats. Neurosci Biobehav Rev 31(6), 874-881.
86. S.W. Looney and R.S. El Mallakh (1997) Meta-analysis of erythrocyte Na,K-ATPase activity in bipolar illness. Depress Anxiety 5(2), 53-65.
87. S.H. Jones (2001) Circadian rhythms, multilevel models of emotion and bipolar disorder – an initial step towards integration? Clin Psychol Rev 21(8), 1193-1209.
88. T.A. Wehr (1989) Sleep loss: A preventable cause of mania and other excited states. J Clin Psychiatry 50(Suppl), 8-16.
89. C.A. Perlman, S.L. Johnson and T.A. Mellman (2006) The prospective impact of sleep duration on depression and mania. Bipolar Disord 8(3), 271-274.
90. A. Laposky, A. Easton, C. Dugovic, J. Walisser, C. Bradfield and F. Turek (2005) Deletion of the mammalian circadian clock gene BMAL1/Mop3 alters baseline sleep architecture and the response to sleep deprivation. Sleep 28(4), 395-409.
91. H. Manev and T. Uz (2006) Clock genes: Influencing and being influenced by psychoactive drugs. Trends Pharmacol Sci 27(4), 186-189.
92. A. Wirz-Justice (2006) Biological rhythm disturbances in mood disorders. Int Clin Psychopharmacol 21(Suppl 1), S11-S15.
93. C.A. McClung (2007) Circadian genes, rhythms and the biology of mood disorders. Pharmacol Ther 114(2), 222-232.
94. S.A. Kaladchibachi, B. Doble, N. Anthopoulos, J.R. Woodgett and A.S. Manoukian (2007) Glycogen synthase kinase 3, circadian rhythms, and bipolar disorder: A molecular link in the therapeutic action of lithium. J Circadian Rhythms 5 3.
95. F. Benedetti, B. Barbini, M.C. Fulgosi, C. Colombo, S. Dallaspezia, A. Pontiggia, et al. (2005) Combined total sleep deprivation and light therapy in the treatment of drug-resistant bipolar depression: Acute response and long-term remission rates. J Clin Psychiatry 66(12), 1535-1540.
96. G.N. Papadimitriou, D.G. Dikeos, C.R. Soldatos and J.R. Calabrese (2007) Non-pharmacological treatments in the management of rapid cycling bipolar disorder. J Affect Disord 98(1–2), 1-10.
97. D. Riemann, U. Voderholzer and M. Berger (2002) Sleep and sleep-wake manipulations in bipolar depression. Neuropsychobiology 45(Suppl 1), 7-12.
98. G.L. Gessa, L. Pani, P. Fadda and W. Fratta (1995) Sleep deprivation in the rat: An animal model of mania. Eur Neuropsychopharmacol 5(Suppl), 89-93.
99. A. Easton, J. Arbuzova and F.W. Turek (2003) The circadian Clock mutation increases exploratory activity and escape-seeking behavior. Genes Brain Behav 2(1), 11-19.
100. K. Roybal, D. Theobold, A. Graham, J.A. Dinieri, S.J. Russo, V. Krishnan, et al. (2007) Mania-like behavior induced by disruption of CLOCK. Proc Natl Acad Sci USA 104(15), 6406-6411.
101. A. Frazer and D.A. Morilak (2005) What should animal models of depression model? Neurosci Biobehav Rev 29(4–5), 515-523.
102. S.H. Jones and N. Tarrier (2005) New developments in bipolar disorder. Clin Psychol Rev 25(8), 1003-1007.
103. S.H. Jones, W. Sellwood and J. McGovern (2005) Psychological therapies for bipolar disorder: The role of model-driven approaches to therapy integration. Bipolar Disord 7(1), 22-32.
104. C.L. Bowden (2005) A different depression: Clinical distinctions between bipolar and unipolar depression. J Affect Disord 84(2–3), 117-125.
105. R. Machado-Vieira, F. Kapczinski and J.C. Soares (2004) Perspectives for the development of animal models of bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 28(2), 209-224.
106. P.J. Goodnick (2007) Bipolar depression: A review of randomised clinical trials. Expert Opin Pharmacother 8(1), 13-21.
107. M. Bourin, F. Masse and M. Hascoet (2005) Evidence for the activity of lamotrigine at 5-HT(1A) receptors in the mouse forced swimming test. J Psychiatry Neurosci 30(4), 275-282.
108. C. Song and B.E. Leonard (2005) The olfactory bulbectomised rat as a model of depression. Neurosci Biobehav Rev 29(4–5), 627-647.
109. D.A. Slattery, A. Markou and J.F. Cryan (2007) Evaluation of reward processes in an animal model of depression. Psychopharmacology (Berl) 190(4), 555-568.
110. C. Song, A.A. Killeen and B.E. Leonard (1994) Catalase, superoxide dismutase and glutathione peroxidase activity in neutrophils of sham-operated and olfactory-bulbectomised rats following chronic treatment with desipramine and lithium chloride. Neuropsychobiology 30(1), 24-28.
111. K.A. Dienes, C. Hammen, R.M. Henry, A.N. Cohen and S.E. Daley (2006) The stress sensitization hypothesis: Understanding the course of bipolar disorder. J Affect Disord 95(1–3), 43-49.
112. S.L. Johnson and J.E. Roberts (1995) Life events and bipolar disorder: Implications from biological theories. Psychol Bull 117(3), 434-449.
113. P. Willner (2005) Chronic mild stress (CMS) revisited: Consistency and behavioural-neurobiological concordance in the effects of CMS. Neuropsychobiology 52(2), 90-110.
114. P. Willner (1997) Validity, reliability and utility of the chronic mild stress model of depression: A 10-year review and evaluation. Psychopharmacology (Berl) 134(4), 319-329.
115. P. Willner, R. Muscat and M. Papp (1992) Chronic mild stress-induced anhedonia: A realistic animal model of depression. Neurosci Biobehav Rev 16(4), 525-534.
116. J.M. Koolhaas, S.F. De Boer, A.J. De Rutter, P. Meerlo and A. Sgoifo (1997) Social stress in rats and mice. Acta Physiol Scand Suppl 640 69-72.
117. M. Razzoli, E. Roncari, A. Guidi, L. Carboni, R. Arban, P. Gerrard, et al. (2006) Conditioning properties of social subordination in rats: Behavioral and biochemical correlates of anxiety. Horm Behav 50(2), 245-251.
118. R. Rygula, N. Abumaria, G. Flugge, E. Fuchs, E. Ruther and U. Havemann-Reinecke (2005) Anhedonia and motivational deficits in rats: Impact of chronic social stress. Behav Brain Res 162(1), 127-134.
119. A. Keeney, D.S. Jessop, M.S. Harbuz, C.A. Marsden, S. Hogg and R.E. Blackburn-Munro (2006) Differential effects of acute and chronic social defeat stress on hypothalamic-pituitary-adrenal axis function and hippocampal serotonin release in mice. J Neuro­endocrinol 18(5), 330-338.
120. M. Razzoli, L. Carboni, A. Guidi, P. Gerrard and R. Arban (2007) Social defeat-induced contextual conditioning differentially imprints behavioral and adrenal reactivity: A time-course study in the rat. Physiol Behav 92(4), 734-740.
121. R. Rygula, N. Abumaria, E. Domenici, C. Hiemke and E. Fuchs (2006) Effects of fluoxetine on behavioral deficits evoked by chronic social stress in rats. Behav Brain Res 174(1), 188-192.
122. R. Rygula, N. Abumaria, G. Flugge, C. Hiemke, E. Fuchs, E. Ruther, et al. (2006) Citalopram counteracts depressive-like symptoms evoked by chronic social stress in rats. Behav Pharmacol 17(1), 19-29.
123. J.C. von Frijtag, B.R. van den and B.M. Spruijt (2002) Imipramine restores the long-term impairment of appetitive behavior in socially stressed rats. Psychopharmacology (Berl) 162(3), 232-238.
124. G.S. Sachs and A.J. Rush (2003) Response, remission, and recovery in bipolar disorders: What are the realistic treatment goals? J Clin Psychiatry 64(Suppl 6), 18-22.
125. W. Coryell (2005) Rapid cycling bipolar disorder: Clinical characteristics and treatment options. CNS Drugs 19(7), 557-569.
126. A.C. Swann, C.L. Bowden, J.R. Calabrese, S.C. Dilsaver and D.D. Morris (2000) Mania: Differential effects of previous depressive and manic episodes on response to treatment. Acta Psychiatr Scand 101(6), 444-451.
127. R.M. Post (1992) Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am J Psychiatry 149(8), 999-1010.
128. R.M. Post, S.R. Weiss, M. Smith, J. Rosen and M. Frye (1995) Stress, conditioning, and the temporal aspects of affective disorders. Ann N Y Acad Sci 771 677-696.
129. R.M. Post (2007) Kindling and sensitization as models for affective episode recurrence, cyclicity, and tolerance phenomena. Neurosci Biobehav Rev 31(6), 858-873.
130. N.F. Idris, P. Repeto, J.C. Neill and C.H. Large (2005) Investigation of the effects of lamotrigine and clozapine in improving reversal-learning impairments induced by acute phencyclidine and D-amphetamine in the rat. Psychopharmacology (Berl) 179(2), 336-348.
131. L.J. Hirsch, D. Weintraub, Y. Du, R. Buchsbaum, H.T. Spencer, M. Hager, et al. (2004) Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy. Neurology 63(6), 1022-1026.
132. B. Rambeck and P. Wolf (1993) Lamotrigine clinical pharmacokinetics. Clin Pharmacokinet 25(6), 433-443.
133. B. Rambeck, U.H. Jurgens, T.W. May, H.W. Pannek, F. Behne, A. Ebner, et al. (2006) Comparison of brain extracellular fluid, brain tissue, cerebrospinal fluid, and serum concentrations of antiepileptic drugs measured intraoperatively in patients with intractable epilepsy. Epilepsia 47(4), 681-694.
134. A.A. Nierenberg, M.J. Ostacher, J.R. Calabrese, T.A. Ketter, L.B. Marangell, D.J. Miklowitz, et al. (2006) Treatment-resistant bipolar depression: A STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry 163(2), 210-216.
135. G.M. Goodwin, C.L. Bowden, J.R. Calabrese, H. Grunze, S. Kasper, R. White, et al. (2004) A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 65(3), 432-441.
136. J. Nissinen and A. Pitkanen (2007) Effect of antiepileptic drugs on spontaneous seizures in epileptic rats. Epilepsy Res 73(2), 181-191.
137. M.M. Castel-Branco, A.C. Falcao, I.V. Figueiredo and M.M. Caramona (2005) Lamotrigine pharmacokinetic/pharmacodynamic modelling in rats. Fundam Clin Pharmacol 19(6), 669-675.
138. M. Schou (2001) Lithium treatment at 52. J Affect Disord 67(1–3), 21-32.
139. R.H. Lenox, R.K. McNamara, R.L. Papke and H.K. Manji (1998) Neurobiology of lithium: An update. J Clin Psychiatry 59(Suppl 6), 37-47.
140. J.C. Ong, S.A. Brody, C.H. Large and M.A. Geyer (2005) An investigation of the efficacy of mood stabilizers in rodent models of prepulse inhibition. J Pharmacol Exp Ther 315(3), 1163-1171.
141. R.S. Fisher (1989) Animal models of the epilepsies. Brain Res Brain Res Rev 14(3), 245-278.
142. J. Sadock and H. Kaplan (2002) Synopsis of Psychiatry. UK: Lippincott and Williams
143. H. Einat (2006) Modelling facets of mania – new directions related to the notion of Endophenotypes. J Psychopharmacol 20(5), 714-722.
144. T.D. Gould, A.M. Picchini, H. Einat and H.K. Manji (2006) Targeting glycogen synthase kinase-3 in the CNS: Implications for the development of new treatments for mood disorders. Curr Drug Targets 7(11), 1399-1409.
145. G. Shaltiel, G. Chen and H.K. Manji (2007) Neurotrophic signaling cascades in the pathophysiology and treatment of bipolar disorder. Curr Opin Pharmacol 7(1), 22-26.
146. H.K. Manji, J.A. Quiroz, J.L. Payne, J. Singh, B.P. Lopes, J.S. Viegas, et al. (2003) The underlying neurobiology of bipolar disorder. World Psychiatry 2(3), 136-146.
147. G. Chen and H.K. Manji (2006) The extracellular signal-regulated kinase pathway: An emerging promising target for mood stabilizers. Curr Opin Psychiatry 19(3), 313-323.
148. P.J. Carlson, J.B. Singh, C.A. Zarate Jr, W.C. Drevets and H.K. Manji (2006) Neural circuitry and neuroplasticity in mood disorders: Insights for novel therapeutic targets. NeuroRx 3(1), 22-41.
149. C.A. Zarate Jr, J. Singh and H.K. Manji (2006) Cellular plasticity cascades: Targets for the development of novel therapeutics for bipolar disorder. Biol Psychiatry 59(11), 1006-1020.
150. R.F. Bachmann, R.J. Schloesser, T.D. Gould and H.K. Manji (2005) Mood stabilizers target cellular plasticity and resilience cascades: Implications for the development of novel therapeutics. Mol Neurobiol 32(2), 173-202.
151. T.D. Gould and H.K. Manji (2005) Glycogen synthase kinase-3: A putative molecular target for lithium mimetic drugs. Neuropsychopharmacology 30(7), 1223-1237.
152. T.D. Gould, J.A. Quiroz, J. Singh, C.A. Zarate and H.K. Manji (2004) Emerging experimental therapeutics for bipolar disorder: Insights from the molecular and cellular actions of current mood stabilizers. Mol Psychiatry 9(8), 734-755.
153. G. Chen, L.D. Huang, Y.M. Jiang and H.K. Manji (1999) The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J Neurochem 72(3), 1327-1330.
154. V. Stambolic, L. Ruel and J.R. Woodgett (1996) Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol 6(12), 1664-1668.
155. F. Benedetti, A. Serretti, A. Pontiggia, A. Bernasconi, C. Lorenzi, C. Colombo, et al. (2005) Long-term response to lithium salts in bipolar illness is influenced by the glycogen synthase kinase 3-beta -50 T/C SNP. Neurosci Lett 376(1), 51-55.
156. T.D. Gould, H. Einat, R. Bhat and H.K. Manji (2004) AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int J Neuropsy­chopharmacol 7(4), 387-390.
157. T.D. Gould, A.M. Picchini, H. Einat and H.K. Manji (2006) Targeting glycogen synthase kinase-3 in the CNS: Implications for the development of new treatments for mood disorders. Curr Drug Targets 7(11), 1399-1409.
158. O. Kaidanovich-Beilin, A. Milman, A. Weizman, C.G. Pick and H. Eldar-Finkelman (2004) Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on beta-catenin in mouse hippocampus. Biol Psychiatry 55(8), 781-784.
159. W.T. O’Brien, A.D. Harper, F. Jove, J.R. Woodgett, S. Maretto, S. Piccolo, et al. (2004) Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium. J Neurosci 24(30), 6791-6798.
160. T.D. Gould, H. Einat, K.C. O’donnell, A.M. Picchini, R.J. Schloesser and H.K. Manji (2007) Beta-Catenin overexpression in the mouse brain phenocopies lithium-sensitive behaviors. Neuropsychopharmacology 32(10), 2173-2783.
161. N. Kozlovsky, C. Nadri, R.H. Belmaker and G. Agam (2003) Lack of effect of mood stabilizers or neuroleptics on GSK-3 protein levels and GSK-3 activity. Int J Neuropsychopharmacol 6(2), 117-120.
162. J.M. Bebchuk, C.L. Arfken, S. Dolan-Manji, J. Murphy, K. Hasanat and H.K. Manji (2000) A preliminary investigation of a protein kinase C inhibitor in the treatment of acute mania. Arch Gen Psychiatry 57(1), 95-97.
163. C.A. Zarate Jr, J.B. Singh, P.J. Carlson, J. Quiroz, L. Jolkovsky, D.A. Luckenbaugh, et al. (2007) Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: A pilot study. Bipolar Disord 9(6), 561-570.
164. I.I. Gottesman and T.D. Gould (2003) The endophenotype concept in psychiatry: Etymology and strategic intentions. Am J Psychiatry 160(4), 636-645.
165. G. Hasler, W.C. Drevets, H.K. Manji and D.S. Charney (2004) Discovering endophenotypes for major depression. Neuropsychopharmacology 29(10), 1765-1781.
166. W.C. Drevets, D. Ongur and J.L. Price (1998) Reduced glucose metabolism in the subgenual prefrontal cortex in unipolar depression. Mol Psychiatry 3(3), 190-191.
167. R.M. Sapolsky (2000) Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry 57(10), 925-935.
168. S. Watson, P. Gallagher, J.C. Ritchie, I.N. Ferrier and A.H. Young (2004) Hypothalamic-pituitary-adrenal axis function in patients with bipolar disorder. Br J Psychiatry 184 496-502.
169. S.M. Brown, S. Henning and C.L. Wellman (2005) Mild, short-term stress alters dendritic morphology in rat medial prefrontal cortex. Cereb Cortex 15(11), 1714-1722.
170. S.C. Cook and C.L. Wellman (2004) Chronic stress alters dendritic morphology in rat medial prefrontal cortex. J Neurobiol 60(2), 236-248.
171. L. Pezawas, B.A. Verchinski, V.S. Mattay, J.H. Callicott, B.S. Kolachana, R.E. Straub, et al. (2004) The brain-derived neurotrophic factor val66met polymorphism and variation in human cortical morphology. J Neurosci 24(45), 10099-10102.
172. M.F. Egan, M. Kojima, J.H. Callicott, T.E. Goldberg, B.S. Kolachana, A. Bertolino, et al. (2003) The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112(2), 257-269.
173. A.R. Hariri, T.E. Goldberg, V.S. Mattay, B.S. Kolachana, J.H. Callicott, M.F. Egan, et al. (2003) Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. J Neurosci 23(17), 6690-6694.
174. H. Einat, H.K. Manji, T.D. Gould, J. Du and G. Chen (2003) Possible involvement of the ERK signaling cascade in bipolar disorder: Behavioral leads from the study of mutant mice. Drug News Perspect 16(7), 453-463.
175. R.M. Post (2007) Role of BDNF in bipolar and unipolar disorder: Clinical and theoretical implications. J Psychiatr Res 41(12), 979-990.
176. D.A. Glitz, H.K. Manji and G.J. Moore (2002) Mood disorders: Treatment-induced changes in brain neurochemistry and structure. Semin Clin Neuropsychiatry 7(4), 269-280.
177. G.J. Moore, J.M. Bebchuk, I.B. Wilds, G. Chen and H.K. Manji (2000) Lithium-induced increase in human brain grey matter. Lancet 356(9237), 1241-1242.
178. A. Jackson, J. Cavanagh and J. Scott (2003) A systematic review of manic and depressive prodromes. J Affect Disord 74(3), 209-217.
179. A.G. Harvey, D.A. Schmidt, A. Scarna, C.N. Semler and G.M. Goodwin (2005) Sleep-related functioning in euthymic patients with bipolar disorder, patients with insomnia, and subjects without sleep problems. Am J Psychiatry 162(1), 50-57.
180. A.G. Harvey, B.C. Mullin and S.P. Hinshaw (2006) Sleep and circadian rhythms in children and adolescents with bipolar disorder. Dev Psychopathol 18(4), 1147-1168.
181. R. Hakkarainen, C. Johansson, T. Kieseppa, T. Partonen, M. Koskenvuo, J. Kaprio, et al. (2003) Seasonal changes, sleep length and circadian preference among twins with bipolar disorder. BMC Psychiatry 3 6.
182. F. Benedetti, B. Barbini, E. Campori, M.C. Fulgosi, A. Pontiggia and C. Colombo (2001) Sleep phase advance and lithium to sustain the antidepressant effect of total sleep deprivation in bipolar depression: New findings supporting the internal coincidence model? J Psychiatr Res 35(6), 323-329.
183. F. Benedetti, A. Serretti, C. Colombo, B. Barbini, C. Lorenzi, E. Campori, et al. (2003) Influence of CLOCK gene polymorphism on circadian mood fluctuation and illness recurrence in bipolar depression. Am J Med Genet B Neuropsychiatr Genet 123(1), 23-26.
184. F. Benedetti, A. Serretti, C. Colombo, C. Lorenzi, V. Tubazio and E. Smeraldi (2004) A glycogen synthase kinase 3-beta promoter gene single nucleotide polymorphism is associated with age at onset and response to total sleep deprivation in bipolar depression. Neurosci Lett 368(2), 123-126.
185. Fletcher, A.J., Edwards, L.D., Fox, A.W., Stonier, P. (2002). Principles and Practice of Pharmaceutical Medicine, John Wiley & Sons, Ltd, London.
186. M.A. Rogawski and W. Loscher (2004) The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat Med 10(7), 685-692.
187. C.L. Bowden and N.U. Karren (2006) Anticonvulsants in bipolar disorder. Aust N Z J Psychiatry 40(5), 386-393.
188. C.L. Bowden (2001) Novel treatments for bipolar disorder. Expert Opin Investig Drugs 10(4), 661-671.
189. C. Hiemke, A. Dragicevic, G. Grunder, S. Hatter, J. Sachse, I. Vernaleken, et al. (2004) Therapeutic monitoring of new antipsychotic drugs. Ther Drug Monit 26(2), 156-160.
190. P. Seeman (2002) Atypical antipsychotics: Mechanism of action. Can J Psychiatry 47(1), 27-38.
191. F. Tergau, S. Wischer, H.S. Somal, M.A. Nitsche, A.J. Mercer, W. Paulus, et al. (2003) Relationship between lamotrigine oral dose, serum level and its inhibitory effect on CNS: Insights from transcranial magnetic stimulation. Epilepsy Res 56(1), 67-77.
192. U. Ziemann (2004) TMS and drugs. Clin Neurophysiol 115(8), 1717-1729.
193. P.M. Rossini and S. Rossi (2007) Transcranial magnetic stimulation: Diagnostic, therapeutic, and research potential. Neurology 68(7), 484-488.
194. X. Li, C.C. Teneback, Z. Nahas, F.A. Kozel, C. Large, J. Cohn, et al. (2004) Interleaved transcranial magnetic stimulation/functional MRI confirms that lamotrigine inhibits cortical excitability in healthy young men. Neuropsychopharmacology 29(7), 1395-1407.
195. W.C. Drevets, C. Gautier, J.C. Price, D.J. Kupfer, P.E. Kinahan, A.A. Grace, et al. (2001) Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. Biol Psychiatry 49(2), 81-96.
196. A. Anand, D.S. Charney, D.A. Oren, R.M. Berman, X.S. Hu, A. Cappiello, et al. (2000) Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: Support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch Gen Psychiatry 57(3), 270-276.
197. C. Norra (2007) Challenge tests of monoaminergic systems: Neurophysiological aspects. Clin EEG Neurosci 38(2), 66-73.
198. L. Booij, A.J. Van der Does and W.J. Riedel (2003) Monoamine depletion in psychiatric and healthy populations: Review. Mol Psychiatry 8(12), 951-973.
199. L. Booij, A.J. Van der Does, P.M. Haffmans and W.J. Riedel (2005) Acute tryptophan depletion in depressed patients treated with a selective serotonin-noradrenalin reuptake inhibitor: Augmentation of antidepressant response? J Affect Disord 86(2–3), 305-311.
200. A.J. Van der Does and L. Booij (2005) Cognitive therapy does not prevent a response to tryptophan depletion in patients also treated with antidepressants. Biol Psychiatry 58(11), 913-915.
201. A. Wirz-Justice and R.H. Van den Hoofdakker (1999) Sleep deprivation in depression: What do we know, where do we go? Biol Psychiatry 46(4), 445-453.
202. H. Giedke and F. Schwarzler (2002) Therapeutic use of sleep deprivation in depression. Sleep Med Rev 6(5), 361-377.
203. J. Cohen, C. Cairns, C. Paquette and L. Faden (2006) Comparing patient access to pharmaceuticals in the UK and US. Appl Health Econ Health Policy 5(3), 177-187.
204. E. Vieta and X. Carne (2005) The use of placebo in clinical trials on bipolar disorder: A new approach for an old debate. Psychother Psychosom 74(1), 10-16.
205. S.J. Wang, R.T. O’Neill and H.M. Hung (2007) Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset. Pharm Stat 6(3), 227-244.
206. M. Tohen, J. Calabrese, E. Vieta, C. Bowden, A. Gonzalez-Pinto, D. Lin, et al. (2007) Effect of comorbid anxiety on treatment response in bipolar depression. J Affect Disord 104(1–3), 137-146.
207. A. Maloney, M.O. Karlsson and U.S. Simonsson (2007) Optimal adaptive design in clinical drug development: A simulation example. J Clin Pharmacol 47(10), 1231-1243.
208. K. Desseaux and R. Porcher (2007) Flexible two-stage design with sample size reassessment for survival trials. Stat Med 26(27), 5002-5013.
209. H. Schmidli, F. Bretz and A. Racine-Poon (2007) Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint. Stat Med 26(27), 4925-4938.